Related Experiment Videos
Use of intravenous gamma-globulin for Kawasaki disease: effects on cardiac sequelae
H Yanagawa1, Y Nakamura, K Sakata
1Department of Public Health, Jichi Medical School, Tochigi-ken, Japan.
Insights
Intravenous gamma-globulin (IVGG) treatment for Kawasaki disease may increase cardiac sequelae risk at doses over 2000 mg/kg or when initiated on day 9 or later. Further research is needed to determine optimal IVGG use.
Area of Science:
- Pediatrics
- Immunology
- Cardiology
Background:
- Kawasaki disease is a critical pediatric illness.
- Intravenous gamma-globulin (IVGG) is a common treatment.
- The optimal IVGG regimen for preventing cardiac sequelae remains unclear.
Purpose of the Study:
- To investigate the administration patterns of IVGG in Japan for Kawasaki disease.
- To analyze the relationship between IVGG dosage, treatment timing, and cardiac sequelae.
- To identify potential risks associated with IVGG treatment protocols.
Main Methods:
- A nationwide survey in Japan during 1993.
- Data collected from 2652 hospitals with >100 beds.
- Analysis of 11,221 reported Kawasaki disease patients receiving IVGG.
Main Results:
- 79.8% of patients received IVGG; common doses were 1000 mg/kg (36.3%), 2000 mg/kg (16.9%), and 1200 mg/kg (16.8%).
- Treatment initiated by day 5 in 53.8% and by day 7 in 83.7% of patients.
- Higher cardiac sequelae rates observed with IVGG doses >2000 mg/kg or treatment initiated on day 9 or later.
Conclusions:
- High-dose IVGG (>2000 mg/kg) or late initiation (day 9+) may be linked to increased cardiac sequelae risk.
- The findings suggest potential unfavorable effects of specific IVGG protocols.
- A prospective randomized controlled trial is necessary to establish optimal IVGG administration for Kawasaki disease.
Abstract:
The administration of intravenous gamma-globulin (IVGG) for Kawasaki disease was investigated throughout Japan in 1993 by obtaining information from pediatric departments in 2652 hospitals that had more than 100 beds. Of 11,221 reported patients, 8958 patients (79.8%) received IVGG treatment. Of all the patients to whom IVGG was administered, the most common total dose was 1000 mg/kg (36.3%) followed by 2000 mg/kg (16.9%) and 1200 mg/kg (16.8%). The treatment was started in 53.8% by day 5 of the illness and in 83.7% by day 7. The proportion of those with cardiac sequelae was higher among patients administered > 2000 mg/kg or in those started on IVGG on day 9 of their illness or later. The possible reasons are (1) those who were more severely affected were treated with high-dose IVGG earlier; or (2) IVGG does not effectively prevent cardiac sequelae. We concluded that there is a risk of unfavorable effects with IVGG regarding cardiac sequelae when the IVGG dose is > 2000 mg/kg or if IVGG is started on day 9 or later. We believe that only a randomized controlled trial, undertaken prospectively, can adequately address the question of the optimal use of IVGG.